来源文献：Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.

PMID:21203568

DOI:10.1371/journal.pone.0015257

Humanized BALB/c-Rag22/2cc2/2 (RAG-hu) mice construction: newborn mice were conditioned by irradiating with 350 rads and then injected intrahepatically with 0.5-16106 human CD34+ cells. Mice werescreened for human cell engraftment at 10–12 weeks postreconstitution. Raltergravir (Isentress) 400 mg, Merck & Co) were freshly dissolved in distilled water each day prior to oral gavage. Mouseequivalent drug doses were calculated by using an interspecies allometric scaling factor of 12.3 to arrive at 164 mg/kg and 62 mg/kg doses for raltegravir and maraviroc respectively. Mice were challenged with HIV-1 vaginally on the 4th day of treatment and the drug treatment continued for 3 more days. For vaginal viral challenges, cell-free HIV-1 strain BaL-1 (R5 tropic virus) contained in the original media used to produce the virus (RPMI 1640 medium supplemented with 10% fetal bovine serum) was used. Vaginal infections were performed in a volume of 20 ml (3000 TCID of BaL-1 virus).

诊断：病毒在血液中复制。

所有感染动物必须在ABSL-3室中进行。

1.该模型制备比较成熟，国内外都有此模型，构建和评价指标一致，所以该模型应用广泛，具有统一的操作规程。

2. 该模型制备的关键：1）小鼠必须是重度免疫缺陷的，而且饲养环境必须洁净；2）HIV操作需要生物安全。

3.此模型具有完善的人的免疫系统，HIV感染后，具有艾滋病病人相似的临床症状，所以具有很高的比较医学应用价值。